Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelitolimod (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Acronyms (PERIO)-03; PERIO-03
  • Sponsors TriSalus Life Sciences

    • Most Recent Events

    • 15 Aug 2024 According to a TriSalus Life Sciences media release, Phase 1 results for this study are anticipated in Q4 2024.
    • 26 Mar 2024 Results presented in a TriSalus Life Sciences Media Release.
    • 26 Mar 2024 According to a TriSalus Life Sciences media release, new safety and feasibility data from this study was presented at the Society of Interventional Radiology Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top